- Org
- MDAndersonPS
- Type
- RFP
- Title
- Discovery and Development of Small Molecules and Biologic Therapies RFP
- Number
- MS-B-01711-RFP
- Source
- MD_ANDERSON
- Status
- Open
- Event Id
- 1462184
- Open Str
- 10/30/2026, 4:30 PM CDT
- Pdf Text
- 30 October 2026
Discovery and Development of Small Molecules and Biologic Therapies RFP
RFP for CROs Supporting the Discovery and Development of Small-Molecule and Biologic Therapies for the
Therapeutic Discovery Division (TDD).
30 October 2026
Released 10/30/2026, 4:00 PM CDT Type Request for Proposal
Open 10/30/2026, 4:30 PM CDT Number MS-B-01711-RFP
Close 12/9/2026, 2:00 PM CST Currency US Dollar
Sealed Until 12/9/2026, 2:00 PM CST
30 October 2026
Contacts
Winston Fitzgerald
WJFitzgerald@mdanderson.org
Phone +1 713-792-1682
30 October 2026
Commodity Codes
Commodity Code Description
85131700 Medical science and research
85131703 Biomedical research services
85131710 Immunology research services
30 October 202630 October 202630 October 202630 October 202630 October 202630 October 202630 October 202630 October 2026
Description
The University of Texas MD Anderson’s (MD Anderson) Therapeutic Discovery Division (TDD) discovers
and develops small molecules and biologic therapies for targeted cancer treatment in defined patient
populations. As a result, this Request for Proposal (RFP) is to obtain Contract Research Organizations
(CRO) who can assist in this process.
Required to View Event
Prerequisites Required to Enter Bid
There are no Prerequisites added to this event.
30 October 202630 October 202630 October 202630 October 202630 October 202630 October 202630 October 2026
Buyer Attachments
1. About MD Anderson
2. Facts and History
3. References
4. MDACC FORM Summary Agreement_RFP.docx
5. Rider 101 - SOW Small Molecule_Final.pdf
6. MDACC FORM 104 - Subcontracting Plan Rev June 2026.pdf
7. MDACC FORM Rider 116 - Invoice Payment Requirements_RFP.docx
8. Vendor Rider Attestation Form.xlsx
9. EO-GA-48 Supplier Certification.pdf
30 October 202630 October 202630 October 202630 October 202630 October 202630 October 2026
Questions Required Questions
Group 1.1: Facts & History
Instructions:
1.1.1
WARNING: To answer this question, you will be navigating away from this page to the "Buyer
Attachments" section of this event. Be sure that you have saved all previous answers by clicking
on the "Save Progress" button before navigating away from this page.
1) Please download and review the MD Anderson's Facts & History under the "Buyer
Attachments" section. The "Buyer Attachments" section can be located on the menu of contents to
the left.
2) When complete reviewing, you can return to this page and acknowledge that you have read it.
Group 1.2: About MD Anderson
Instructions:
1.2.1
WARNING: To answer this question, you will be navigating away from this page to the "Buyer
Attachments" section of this event. Be sure that you have saved all previous answers by clicking
on the "Save Progress" button before navigating away from this page.
1) Please download and review About MD Anderson under the "Buyer Attachments" section. The
"Buyer Attachments" section can be located on the menu of contents to the left.
2) When complete reviewing, you can return to this page and acknowledge that you have read it.
Group 2.1: Addendums
Instructions:
2.1.1
This page contains any new information about the RFP after the published date. If there
are any changes to the RFP, it will be documented here. If you receive an e-mail or an
online notification (if logged into MD Anderson Sourcing Director) with the subject the
line "The Sourcing Event is Amended", please visit this page for any important changes
to the event.
Group 3.1: Scope of Work
Instructions:
3.1.1
WARNING: To answer this question, you will be navigating away from this page to the
"Buyer Attachments" section of this event. Be sure that you have saved all previous
answers by clicking on the "Save Progress" button before navigating away from this
page.
Please download and review Scope of Work. After reviewing, acknowledge that you
have read it.
Group 4.1: General Information
Instructions:
4.1.1
WARNING: To answer this question, you will be navigating away from this page to the
"Buyer Attachments" section of this event. Be sure that you have saved all previous
answers by clicking on the "Save Progress" button before navigating away from this
page.
Please download and review the General Information. After reviewing, acknowledge
that you have read it.
Group 4.2: Point-of-Contact
Instructions:
4.2.1
The Owner designates the following person, as its representative and Point-of-Contact
for this RFP. Respondents shall direct all communications with the Owner, including
any questions regarding this RFP or its terms and conditions, exclusively to the
designated Point of Contact:
Winston Fitzgerald, Sourcing Specialist
Phone: 713-792-1682
Email: wjfitzgerald@mdanderson.org.
Address: MD Anderson Cancer Center, 7007 Bertner Ave., Houston, Texas
77030-3907 - Note: All communication should be through the MD Anderson Sourcing
Director Q&A area.
Group 4.3: Pre-Proposal Meeting
Instructions:
30 October 202630 October 202630 October 202630 October 202630 October 2026
4.3.1
A Pre-Proposal Meeting will be held at the time and location described: DATE:
November 10, 2026 at 12:30 PM (CST). LOCATION: Zoom Meeting (details below).
This will be the only opportunity for potential respondents to meet and ask questions
directly from the users before submitting a Proposal. Attendance at the Pre-Proposal
Meeting is "highly recommended". Suppliers will need to RSVP no later than November
9, 2026, at 4:00 PM (CST), to wjfitzgerald@mdanderson.org. Suppliers are limited to no
more than two (2) representatives per company. UNAUTHORIZED USE OF
RECORDING DEVICES: "All video and audio recordings, including AI or bot
note-taking, of any meetings and/or presentations are prohibited by MD Anderson.
Meeting URL:
https://mdacc.zoom.us/j/99945163040?pwd=YP7eax0Uz87cWO94fzjozA41e6Zug9.1&f
rom=addon Meeting ID: 999 4516 3040
Password:707814
Phone one-tap: US: +13462487799,,99945163040#,,,,0#,,707814# or
+12532158782,,99945163040#,,,,0#,,707814#
Group 4.4: Disclosure of Interested Parties Mandated by House Bill 1295
Instructions:
4.4.1
MD Anderson must comply with the Disclosure of Interested Parties mandated by
House Bill 1295 and as implemented by the Texas Ethics Commission. Before MD
Anderson may execute a contract exceeding $1M, the Supplier(s) with which MD
Anderson is contracting must submit a completed Form 1295 before or concurrent with
Supplier submission of the signed contract to MD Anderson. For more information,
please use the following link: https://www.ethics.state.tx.us/filinginfo/1295/
Group 4.5: Disclosure of Interested Parties Mandated Senate Bill 475
Instructions:
4.5.1 Please read and review the attached Disclosure of Interested Parties Mandated Senate
Bill 475. Upon completion please acknowledge.
Group 4.6: Public Information Act (PIA)
Instructions:
4.6.1
All information, documentation, and other material submitted in response to this RFP
solicitation is considered non-confidential and/or non-proprietary and is subject to public
disclosure under the Texas Public Information Act (Texas Government Code, Chapter
552.001, et seq.) after the agreement is executed. MD Anderson strictly complies with
all statutes, court decisions, and opinions of the Texas Attorney General with respect to
disclosure of RFP information.
Group 4.7: Best Value
Instructions:
4.7.1
MD Anderson may select the Proposal(s) that offers the "Best Value" for the institution
based on the published selection criteria, its evaluation ranking, and the terms of Texas
Government Code 2155.074.
MD Anderson may first attempt to negotiate a contract with the selected Supplier(s).
MD Anderson may also discuss with the selected Supplier(s) options for a scope or
time and price change modification.
If MD Anderson and/or its governing Board(s) are unable to reach a contract with the
selected Supplier(s) in a timely manner, MD Anderson may formally end negotiations
with that Supplier(s) and proceed to the next "Best Value" Supplier(s) in order of the
selection ranking until a contract is reached or all Proposals are rejected.
Group 4.8: Historically Underutilized Business Submittal Requirements
Instructions:
4.8.1
It is the policy of the Texas Comptroller of Public Accounts to encourage the use of
Historically Underutilized Businesses (HUBs) by state agencies and to assist agencies
in the implementation of this policy through race-, ethnic-, and sex-neutral means. The
purpose of the HUB program is to promote full and equal business opportunities for all
businesses. Accordingly, MD Anderson has adopted the Rider 104 Subcontracting
Plan, Policy on Utilization of Historically Underutilized Businesses. This Policy applies
to all contracts with an expected (cumulative) value of $100,000 or more. If MD
Anderson determines that subcontracting opportunities are probable, then a
Subcontracting Plan is a required element of the Proposal.
Failure to submit a required Subcontracting Plan with the Proposal will result in the
proposal being deemed non-responsive and will not be evaluated.
Group 4.9: HUB Statement of Probability
Instructions:
30 October 202630 October 202630 October 202630 October 202630 October 2026
4.9.1
MD Anderson has determined that subcontracting opportunities are probable in
connection with this solicitation. Therefore, a Subcontracting Plan (SP) is required as
part of Respondent’s Proposal. Each RFP Respondent shall complete and submit a
Subcontracting Plan as part of the Proposal in accordance with MD Anderson's Policy
on Utilization of Historically Underutilized Businesses (HUB) and Rider 104
Subcontracting Plan.
A proposal that does not include a complete Subcontracting Plan at the time of
submission will be considered non-responsive and will not be evaluated.
Group 4.10: Type of Contract
Instructions:
4.10.1
Any contract resulting from this solicitation will be governed by MD Anderson's
Standard Terms and Conditions referenced in the Summary Agreement attached to this
RFP.
The work associated with this RFP will be awarded as a contract to the Supplier(s)
offering the "Best Value" to MD Anderson.
Group 4.11: Selection Criteria
Instructions:
4.11.1
The successful Supplier(s) selected by MD Anderson, in accordance with the
requirements and specifications set forth in this RFP, will be the Supplier(s) which is
most advantageous to MD Anderson. MD Anderson's committee members, comprised
of key personnel as well as Supply Chain professionals, will evaluate and score
approved Proposals.
Group 4.12: MD Anderson's Reservation of Rights
Instructions:
4.12.1
MD Anderson may evaluate the Proposals based on the anticipated completion of all or
any portion of the RFP. MD Anderson reserves the right to divide the RFP into multiple
parts, to reject any and all Proposals and re-solicit for new Proposals, or to reject any
and all Proposals and temporarily or permanently abandon the RFP. MD Anderson
makes no representations, written or oral, that will enter into any form of agreement
with Supplier(s) for this RFP. No such representation is intended or should be
construed by the issuance of this RFP.
Group 4.13: Obligation
Instructions:
4.13.1
Neither the transmission of this RFP to a prospective Supplier(s), nor the acceptance of
a reply, implies any obligation or commitment by MD Anderson to enter into any
contract or undertake any financial obligations with respect to this RFP. After evaluation
of all Proposals, MD Anderson intends to conduct negotiations with the Supplier(s)
considered best qualified and "Best Valued" to meet its requirements. MD Anderson
reserves the right to reject any or all proposals whenever such actions are in its best
interest.
Group 4.14: No Reimbursement for Costs
Instructions:
4.14.1 Supplier(s) acknowledges and accepts that any cost incurred from the Supplier(s)
participation in this RFP process shall be at the sole risk and responsibility of the
Supplier(s). Supplier(s) submit Proposals at their own risk and expense.
Group 4.15: Clarification and Interpretation
Instructions:
4.15.1
Any clarifications or interpretations of this RFP that materially affect or change its
requirements will be issued by MD Anderson as an Addendum.
It is the responsibility of all Supplier(s) to obtain this information in a timely manner. All
such Addenda will be due prior to the RFP Close Date.
Addenda may be issued by the RFP Point-of-Contact via the SciQuest Sourcing
Director Q&A Board or in the Addendum section of this RFP.
All communication specific to this RFP shall be exchanged within the SciQuest tool.
Group 4.16: Certain Proposals and Contracts Prohibited
Instructions:
30 October 202630 October 202630 October 202630 October 202630 October 2026
4.16.1
Under Section 2155.004, Texas Government Code, a state agency may not accept a
Proposal or award a contract that includes proposed financial participation by a person
with received compensation from the agency to participate in preparing the
specifications or request for Proposal on which the Proposal or contract is based.
All Supplier(s) must certify their eligibility by acknowledging the following statement:
"Under Section 2155.004, Government Code, Supplier(s) certifies that the individual or
business entity named in this RFP or contract is not ineligible to receive the specified
contract and acknowledges that this contract may be terminated and payment withheld
if this certification is inaccurate.
Group 4.17: Certain Proposals and Contracts Prohibited (cont...)
Instructions:
4.17.1
If a state agency determines that an individual or business entity holding a state
contract was ineligible to have the contract, yet accepted the award as described
above, the state agency may immediately terminate the contract without further
obligation to the Supplier(s). This does not create a cause of action to contest a
Proposal or award of a state contract.
Group 4.18: Acceptance or Rejection of Proposal
Instructions:
4.18.1
This RFP is not an offer to contract. Acceptance of a Proposal neither commits MD
Anderson to award a contract to any RFP Respondent, nor limits MD Anderson's rights
to negotiate terms in its best interest. MD Anderson reserves the right to accept or
reject any or all Proposals in part or whole. MD Anderson reserves the right to request
clarification on responses, omissions, or claims made in the RFP. MD Anderson further
reserves the right to request modification to a Supplier(s) Proposal in order to provide
the optimum solution for strategic team planning.
Respondents submitting a Proposal do so with the understanding that MD Anderson
reserves the right to select one or more "Supplier(s) of choice" based solely on their
RFP response or to evaluate one or more Supplier(s) via additional interviews, site
visits, reference checks, and other evaluations.
MD Anderson will notify Suppliers of the results when final decisions have been made.
Group 4.19: Electronic Information and Technology (EIT)
Instructions:
4.19.1
Any acquisition considered EIT as defined by Section 508 (36 CFR Part 1194) requires
the submission of a completed Voluntary Accessible Product Template so that can MD
Anderson can ascertain conformance with the applicable EIT standards developed by
the U.S. Access Board. MD Anderson reserves the right to perform real-world testing of
a Supplier's product or service in order to validate claim regarding Section 508
conformance.
In order to facilitate this testing, Supplier(s) shall, upon request, provide MD Anderson a
copy of the product being considered for purchase for a period of at least 30 calendar
days. The version of the product being provided for testing purposes must be
equivalent in functionality and features to the commercial version that is under
consideration for purchase.
MD Anderson, at its sole discretion, will determine the level of conformance with
Section 508 on all products being reviewed.
Group 4.20: Submission of Proposals
Instructions:
4.20.1
MD Anderson is to receive all Supplier(s) Proposals by the RFP close date
communicated within the SciQuest Sourcing Director tool.
Proposals not received within the specified time frame, and prior to the RFP close date
and time, will not be accepted. Supplier(s) are urged not to wait until the last minute to
submit their final Proposal.
Proposals and final HUB Plans submitted via telephone, fax, or electronic mail (email)
will be rejected. Only those submitted via this tool will be accepted.
Respondents must provide a response to all "REQUIRED" questions or the system will
not accept the submission.
Group 4.21: Group Purchasing
Instructions:
30 October 202630 October 202630 October 202630 October 202630 October 2026
4.21.1
MD Anderson is an institution of System which consists of nine academic and six health
institutions. Texas law authorizes institutions of higher education (defined by Section
61.003, Education Code) to use the group purchasing procurement method (ref.
Sections 51.9335, 73.115 and 74.008, Education Code).
With this, if an Agreement results from this competitive procurement method, the RFP
Respondent acknowledges that additional Texas institutions of higher education may
procure from the RFP Respondent and/or Contractor the goods and services set forth
in this RFP/Agreement on the same terms and conditions attached herein by entering
into a separate contract with RFP Respondent/Contractor, or by concluding an
appropriate addendum to the Agreement.
Group 4.22: Group Purchasing (cont...)
Instructions:
4.22.1
It is understood that:
(I) Unless specifically stated otherwise, any volume of goods or services stated in the
final Agreement reflects only goods and/or services to be purchased by MD Anderson
and does not include potential purchases by other System institutions, and
(II) Each System institution is a financially separate entity and will be solely responsible
for its own commitments to Contractor.
Group 5.1:
Instructions:
5.1.1 Please read and review the attached Summary Agreement. Upon completion, please
acknowledge.
5.1.2 Please explain any exceptions to Summary Agreement above by uploading your
redlines for this document in a MSWord. If you have no exceptions, please upload the
document with the words "NO EXCEPTIONS" written on it.
5.1.3 Please read and review Rider 116 - Invoice Payment Requirements. Upon completion,
please acknowledge.
5.1.4 Please explain any exceptions to Rider 116 - Invoice Payment Requirements by
uploading your redlines for this document in a MSWord. If you have no exceptions,
please upload the document with the words "NO EXCEPTIONS" written on it.
5.1.5 Please download the attached EO-GA-48 Supplier Certification Form. After reviewing,
please complete and upload your signed document
Group 6.1:
Instructions:
6.1.1
Please download, complete all applicable pages, "sign and date" the attached Rider
104 HUB Subcontracting Plan.
NOTE: A NEW Rider 104 "must be" submitted with each new RFP.
ALL submissions to this RFP without a properly completed/attached HUB Plan will be
“REJECTED” and will not be eligible for consideration by MD Anderson.
6.1.2 Please download and follow the instructions on the attached Rider 104 HUB
Subcontracting Plan Tip Sheet. This Tip Sheet is designed to aid in the completion of
Rider 104.
Group 7.1: Collaboration & Innovation
Instructions:
7.1.1 Will your company provide Business Reviews, upon request by MD Anderson, with
detailed reporting on contract spend and performance metrics?
7.1.2 State any challenges your company has experienced in implementing a relationship in
similar environments and describe the solution.
7.1.3 Briefly describe your company's competitive advantage in the marketplace. Please
provide only information not previously asked or disclosed herein.
7.1.4 How have you incorporated feedback from clients in your processes?
7.1.5 In the context of a long-term relationship, what benefits would MD Anderson derive
from your company's Research and Development efforts?
Group 7.2: Delivery and Lead Time
Instructions:
7.2.1 Where are your companies primary facilities located?
7.2.2 How does your company deal with unexpected product shortages?
30 October 202630 October 202630 October 202630 October 202630 October 2026
7.2.3 Please describe your company's procedure for notifying MD Anderson in advance of
any partial orders or shipping delays.
7.2.4 Please describe your company's process for order tracking.
7.2.5 What type of communication methods does your company typically employ for
notification?
7.2.6 What is the on-time delivery performance for major project shipments?
Group 7.3: Quality, Health and Safety
Instructions:
7.3.1
Please identify any contracts your company had for similar products and/or services
with institutions of higher learning that were prematurely terminated prior to completion
within the last three years. If any, include the circumstances surrounding such early
termination(s).
7.3.2 Provide any details of all past or pending litigation arising from your Company
furnishing an item or service similar to that described in this RFP.
7.3.3 Has your Company, or any of its parents or subsidiaries, ever had a Bankruptcy
Petition filed in its name, voluntarily or involuntarily? If yes, please explain.
7.3.4 Is Company or any of its parents or subsidiaries, in the midst of a Bankruptcy? If yes,
please explain.
7.3.5 Is your Company currently in default on any loan agreement or financing agreement
with any bank, financial institution, or other entity? If yes, please explain.
7.3.6 Is your company currently for sale or involved in any transaction to expand or to
become acquired by another business entity? If yes, please explain.
7.3.7 Please describe your company's efforts to use environmentally friendly products.
7.3.8 Please describe your company's green product offerings.
7.3.9 Does your company hold certification(s) in any of the ISO families?
If yes, please list all that apply.
7.3.10 Please name three operating procedures or best practices implemented in the past
three years that improved your quality of product and/or service.
7.3.11 What is your company's product recall history?
7.3.12 Please describe your company's quality assurance program and how the program is
measured.
Group 7.4: Service and Support
Instructions:
7.4.1 Provide two financial references (1 trade reference and 1 financial institution/bank
reference). List should include Company Name, Mailing Address, Telephone Number,
FAX Number, Contact Person and Length of Financial Relationship.
7.4.2 Can your company service MD Anderson and all of its satellites and affiliates?
7.4.3 Will your company assign a senior account manager to manage the overall contractual
relationship?
7.4.4 What is the average response time for an account manager(s) to respond to initial
requests?
7.4.5 Please detail your company's problem resolution process for customer complaints and
concerns.
7.4.6 Does your company have a toll free customer service call center and is it based in the
United States? If not, where is it located?
7.4.7 What are the hours of operations for your company's customer service/call center
support line?
7.4.8 Describe any conflicts with the subcontracts or third-party provider and describe the
methods used to resolve those conflicts.
7.4.9 What type of National Account program (for large value customers) are available?
Please be specific and detailed.
7.4.10 How many years has your company been generating/providing the proposed
products/services?
7.4.11 Where is your company's product(s) manufacturered?
7.4.12 What is your company's return policy? Please be specific and detailed.
7.4.13 What is your company's process for a recalled product? Please be specific and
detailed.
7.4.14 Will your company offer a customized monthly, quarterly, annually billing options? If
no, please explain. 30 October 202630 October 202630 October 202630 October 202630 October 2026
Group 7.5: Total Cost of Ownership
Instructions:
7.5.1 Is your company currently a member of a Group Purchasing Organization (Premier),
Texas Department of Information Resources, or TxMAS? If yes, which group?
7.5.2 What were your company's revenues for the last three fiscal years?
7.5.3 What is the framework and process for establishing price discounts with large value
and academic customers?
7.5.4 In the context of a long-term relationship, what benefits, other than cost, would MD
Anderson derive from you company supplying all our commodities within defined
categories? Separate and define the categories as appropriate.
7.5.5 Does your company have the capability to analyze MD Anderson spend and make
recommendations to alternative product and/or services to reduce costs?
7.5.6 Does your company have a published list price for products sold?
7.5.7 How often does pricing change for your company's products sold?
7.5.8 Please describe market factors that determine pricing changes for your company's
products sold?
7.5.9 Please describe strategies your company employs to minimize the impact of negative
movement in the markets (price increases) for raw materials and maximize the value of
positive movement in markets (price decrease) for raw materials.
7.5.10 Please state how your company will maintain its competitive "best value" price and
non-price offering long-term.
7.5.11 MD Anderson is requesting fixed pricing for the term of this agreement. Can your
company agree to this? If no, can your company provide fixed pricing for a set period of
time? Provide a detail explanation of that time frame.
7.5.12 If your company is unable provide fixed pricing for a set period of time, please explain
why.
Group 8.1: Background - How to Bid
Instructions:
8.1.1
HOW TO BID. This RFP is divided into four (4) stages. Suppliers may choose to bid on
one stage or have multiple submission for the various stages. However, in order for
your submission to be considered, you must answer ALL QUESTIONS within that
specific stage/phase of the RFP.
Group 8.2: Collaboration & Innovation
Instructions:
8.2.1 How many and what types of drug discovery organizations have contracted with you in each of the
past 5 years, and overall how long has your organization been providing contractual synthetic FFS
support to external drug discovery organizations?
8.2.2 What are your company's competitive advantages over your main competitors in the provision of
compound synthesis and associated support services?
8.2.3
Please describe the purification and analytical instrumentation and methods used by your team,
including capabilities for chiral compounds and Supercritical Fluid Chromatography (SFC) (and the
scale to which SFC purifications can be conducted), the specialized instrumentation available (for
example hydrogenation apparatus, microwaves, photochemistry, electrochemistry, flow
chemistry), and what information is typically included in your final compound reports.
8.2.4 What are your team's capabilities in the area of high throughput experimentation?
8.2.5 Please describe your process of obtianing starting materials, including which suppliers you use on
a regular basis.
8.2.6 Please describe your process of devising new synthetic routes when not supplied by the client,
and your process for troubleshooting diificult reactions or reaction sequences.
Group 8.3: Delivery and Lead Time
Instructions:
8.3.1 Please give a detailed description of your company's process for contract implementation and
start-up, including the process and lead time for initiating a new target synthesis once the contract
is in place.
8.3.2 Please describe project management in your organization, including how many projects does the
average project manager/leader oversee at any one time.
8.3.3 Are customers and their consultants allowed to visit your site?
8.3.4 How does your company deal with unexpected slot shortages?
Group 8.4: Quality, Health and Safety
Instructions:
30 October 202630 October 202630 October 202630 October 202630 October 2026
8.4.1 Please describe your staff safety training program, Hazmat response plan, and environmental
health and safety policies/procedures.
8.4.2
Please describe the make-up of a typical FFS project team in terms of the number of technician
grade, BSc/MSc and PhD staff and their years of drug discovery and contract research
experience; whether the client is furnished with representative CVs/resumes for the chemists at
the start of a project to help select their team; and how performance issues are managed.
Group 8.5: Service and Support
Instructions:
8.5.1 Please provide two scientific customer's references, including company name, mailing address,
telephone number, FAX number, contact person and length of financial relationship.
8.5.2 Please describe the overall make-up of your facility or facilities, including locations, size, lab
composition (# of chemists per fumehood, # of PhD vs MSc/BA/tech) and the largest scale
reactions you are able to run.
8.5.3 Please describe your preferred communication processes between your teams and the clients, the
IT solutions you use to share data/information with clients, and whether clients have access to
your electronic lab notebooks.
8.5.4 Please describe your records retention policy.
Group 8.6: Total Cost of Ownership
Instructions:
8.6.1 Would your organization accept risk sharing projects whereby your organization and MDACC
move projects towards clinical candidate nomination with each party covering their own costs to be
compensated downstream at a partnering/out-licensing event? If yes, please provide details.
Group 8.7: Pricing
Instructions:
8.7.1
1) Please download and follow the instructions on the attached Rider 102 - Price Schedule.
2) Upon completion, please upload the completed Rider 102 - Price Schedule. ** Pricing "must be"
submitted in this MS Excel format. ANY OTHER FORMAT WILL BE REJECTED.
Group 8.8: Vendor Affirmation
Instructions:
8.8.1 Please download the attached Vendor Rider Attestation Form. After reviewing, please complete
and upload your signed acknowledgement
Group 8.9: References
Instructions:
8.9.1 Please download the attached References file. After reviewing the directions, please complete and
upload the file.
Group 8.10: Miscellaneous / Value Add
Instructions:
8.10.1 Please use this section to upload any “Value-Added” material(s) related to your company. To
upload multiple files, please zip your files into one single .zip file before uploading.
Group 9.1: Background - How to Bid
Instructions:
9.1.1
HOW TO BID. This RFP is divided into four (4) stages. Suppliers may choose to bid on
one stage or have multiple submission for the various stages. However, in order for
your submission to be considered, you must answer ALL QUESTIONS within that
specific stage/phase of the RFP.
Group 9.2: Collaboration & Innovation
Instructions:
9.2.1 How many and what types of drug discovery organizations have contracted with you in each of the
past 5 years, and overall how long has your organization been providing contractual MedChem
support to external drug discovery organizations?
9.2.2 What are your company's competitive advantages over your main competitors in the provision of
medicinal chemistry, compound synthesis and associated support services?
9.2.3
Please describe the purification, analytical, and specialized instrumentation used by your team -
including how many units per chemist, and specialized equipment such as hydrogenation
apparatus, microwaves, photochemistry, electrochemistry and flow chemistry - and describe your
in-house library of commercial reagents, including the amount/scope of proprietary synthetic
building blocks.
9.2.4 What are your team's capabilities in the areas of high throughput experimentation and chemical
library synthesis?
30 October 202630 October 202630 October 202630 October 202630 October 2026
9.2.5 What metrics are used to evaluate the productivity of your team members, what expectations do
you place on them, and how are performance issues managed?
9.2.6 Does your organization have the capability to do in-house ADME/PK studies; if yes then please
briefly describe your capabilities including, if applicable, formulation screening and evaluation of
antibody-drug conjugates.
Group 9.3: Delivery and Lead Time
Instructions:
9.3.1 Please give a detailed description of your company's process for contract implementation and
start-up, including the process and the lead time required to modify the number of FTEs being
contracted by the client.
9.3.2 Describe project management in your organization, including how many projects does the average
project manager/leader oversee at any one time.
9.3.3 Are customers and their consultants allowed to visit your site?
Group 9.4: Quality, Health and Safety
Instructions:
9.4.1 Please describe your staff safety training program, Hazmat response plan, and environmental
health and safety policies/procedures.
9.4.2
Please describe the make-up of your facility or facilities (locations, size, and lab composition - e.g.
chemists per fume hood, # of PhD vs MSc/BA/tech, ability to conduct large scale reactions) and
the make-up of a typical 10-person project team (education levels, years and type of experience,
and percentage speaking English). At the start of a project, is the client furnished with
representative CVs/resumes for the chemists in order to help select their team?
Group 9.5: Service and Support
Instructions:
9.5.1 Please provide two scientific customer's references, including company name, mailing address,
telephone number, FAX number, contact person and length of financial relationship.
9.5.2
Please describe your preferred communication processes between your teams and the client, the
IT solutions you use to share data/information with clients, whether clients have access to your
electronic lab notebooks, and whether your chemistry group can generate SD files in the V3000
format using enhanced stereochemistry on a weekly basis to our specifications to support
compound delivery.
9.5.3 Please describe your records retention policy.
Group 9.6: Total Cost of Ownership
Instructions:
9.6.1 Would your organization accept risk sharing projects whereby your organization and MDACC
move projects towards clinical candidate nomination with each party covering their own costs to be
compensated downstream at a partnering/out-licensing event? If yes, please provide details.
Group 9.7: Pricing
Instructions:
9.7.1
1) Please download and follow the instructions on the attached Rider 102 - Price Schedule.
2) Upon completion, please upload the completed Rider 102 - Price Schedule. ** Pricing "must be"
submitted in this MS Excel format. ANY OTHER FORMAT WILL BE REJECTED.
Group 9.8: Vendor Affirmation
Instructions:
9.8.1 Please download the attached Vendor Rider Attestation Form. After reviewing, please complete
and upload your signed acknowledgement
Group 9.9: References
Instructions:
9.9.1 Please download the attached References file. After reviewing the directions, please complete and
upload the file.
Group 9.10: Miscellaneous / Value Add
Instructions:
9.10.1 Please use this section to upload any “Value-Added” material(s) related to your company. To
upload multiple files, please zip your files into one single .zip file before uploading.
Group 10.1: Background - How to Bid
Instructions:
30 October 202630 October 202630 October 202630 October 202630 October 2026
10.1.1
HOW TO BID. This RFP is divided into four (4) stages. Suppliers may choose to bid on
one stage or have multiple submission for the various stages. However, in order for
your submission to be considered, you must answer ALL QUESTIONS within that
specific stage/phase of the RFP.
Group 10.2: Collaboration & Innovation
Instructions:
10.2.1 Briefly decribe your overall business, and where ADME/DMPK fits into the overall corporate
mission
10.2.2 What were your projected company revenues for 2026?
10.2.3 Who are your main competitors?
10.2.4 Do you identify single scientists to be the primary point of contact for a customer to discuss
study-related issues?
10.2.5 Describe your capabilities to perform studies in multiple species.
Group 10.3: Delivery and Lead Time
Instructions:
10.3.1 Describe the usual time involved to deliver final study reports from study completion.
10.3.2 Are technical staff usually the primary contact for discussions with customer scientists, or do you
use senior staff for these communications?
10.3.3 Describe project management within your organization.
10.3.4 Describe the process for intiating/designing new studies.
10.3.5 From a completed study outline prepared by the customer, what is the typical lead time to start a
study?
10.3.6 How quickly are excel spreadsheets of data made available to customer scientists after creation?
Are there shared in real time as the data become available, or do you have an internal quality
review first?
10.3.7 How many projects do technical staff/senior scientists oversee at any one time?
10.3.8 Generally, how available are your technical/scientific staff to customer scientists and what are
typical response times for study-related customer questions?
10.3.9 Please describe PK modeling and simulations capabilities.
Group 10.4: Quality, Health and Safety
Instructions:
10.4.1 Are customers and their consultants allowed on site?
10.4.2 Are customers and their consultants allowed to talk to any member of team/staff, including
technicians?
10.4.3 Are you able to provide written reports in English?
10.4.4 Are you FDA and OECD compliant?
10.4.5 Describe the make up of your IACUC team, and inspection schedule.
10.4.6 Describe your scientific leadership team, together with their educational background and years
experience at your company, and post-education training. Please include percentage of BS and
PhD staff.
10.4.7 Describe your document and sample/tissue retention policies.
10.4.8 Describe your lab notebook policies (e-notebook, backup/retention and countersigning policy).
10.4.9 Do you have AAALAC accreditation?
10.4.10 Describe your vivarium. Is this a facility dedicated to your use or is it shared with other areas?
10.4.11 When was the last FDA inspection? Describe any findings (including any 483 forms issued) and
what steps have been taken to remedy them.
Group 10.5: Service and Support
Instructions:
10.5.1 Describe the on-site veterinary health capabilities that support colony health.
10.5.2 Describe any contamination/infections occurring in the animal facility in last 3 years.
10.5.3 Describe the size of the animal facility, how it is organized, and number/types of animals housed
at any one time (breakdown per year).
10.5.4 Describe how your animals are obtained, including breeding in-house versus purchased (provide
supplier names).
10.5.5 Do you have the capability to assist in finding appropriate formulations to use for exploratory PK
studies?
30 October 202630 October 202630 October 202630 October 202630 October 2026
10.5.6 Describe your capabilities to perform exploratory PK studies in a variety of species with various
dosing routes (IV, oral, topical, other).
10.5.7 Do your capabilities include both small molecules and drug-antibody conjugates?
10.5.8 Describe the in vitro ADME studies you are capable of running and how these studies conform to
recent FDA guidelines.
10.5.9 Do you have ability to run non-rodent exploratory PK studies (which species/strains)?
10.5.10 Do you have ability to run exploratory rodent PK studies (which species/strains)?
10.5.11 Geographicaly where are the in vivo studies conducted?
10.5.12 What is the proportion of exploratory studies run annually compared to GLP-compliant studies?
10.5.13 Describe your capabilities to conduct mechanistic in vivo studies (eg, bile duct cannulation and/or
metabolic cages, variable dosing regimens, special strains of rodents).
10.5.14 Are in-life and bioanalytical capabilities at the same site?
10.5.15 What is the percentage of staff turnover per year?
10.5.16 What is the total level of staffing for in vitro ADME versus PK/bioanalytical work?
Group 10.6: Total Cost of Ownership
Instructions:
- Close Str
- 12/9/2026, 2:00 PM CST
- Contact Name
- Winston Fitzgerald
- Description
- RFP for CROs Supporting the Discovery and Development of Small-Molecule and Biologic Therapies for the Therapeutic Discovery Division (TDD).
- Contact Email
- wjfitzgerald@mdanderson.org
- Sci Docs Fetched
- Yes
MD Anderson Cancer CenterIssuing agency·Houston, TX·via the MD Anderson SciQuest procurement portal